ARTICLE | Product Development
Why Loxo is leaning on internal discovery as Lilly’s R&D unit
Loxo is building a home-grown oncology pipeline, but it’s open to new technology deals
March 13, 2021 1:50 AM UTC
Loxo has expanded resources under Lilly’s wing and a new CEO at the helm, but it isn’t straying from the home-grown, concentrated pipeline strategy that made it successful as a biotech.
Jacob van Naarden, who stepped in as CEO of the Loxo Oncology unit of Eli Lilly and Co. (NYSE:LLY) after founding CEO Josh Bilenker departed last month, told BioCentury he plans to use the resources to build internal discovery and run a larger number of clinical programs in parallel, while still maintaining the strategy that brought two Loxo drugs from preclinical development to the market in seven years...
BCIQ Company Profiles